ZA914727B - Polycyclic guanine derivatives - Google Patents
Polycyclic guanine derivativesInfo
- Publication number
- ZA914727B ZA914727B ZA914727A ZA914727A ZA914727B ZA 914727 B ZA914727 B ZA 914727B ZA 914727 A ZA914727 A ZA 914727A ZA 914727 A ZA914727 A ZA 914727A ZA 914727 B ZA914727 B ZA 914727B
- Authority
- ZA
- South Africa
- Prior art keywords
- aryl
- alkyl
- heteroaryl
- hydrogen
- pct
- Prior art date
Links
- -1 Polycyclic guanine derivatives Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000005122 aminoalkylamino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 230000003276 anti-hypertensive effect Effects 0.000 abstract 1
- 230000003182 bronchodilatating effect Effects 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Filtering Materials (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54156890A | 1990-06-21 | 1990-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA914727B true ZA914727B (en) | 1992-03-25 |
Family
ID=24160139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA914727A ZA914727B (en) | 1990-06-21 | 1991-06-19 | Polycyclic guanine derivatives |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5393755A (enExample) |
| EP (1) | EP0538332B1 (enExample) |
| JP (1) | JPH0747589B2 (enExample) |
| KR (1) | KR960004532B1 (enExample) |
| AT (1) | ATE155786T1 (enExample) |
| AU (1) | AU651607B2 (enExample) |
| CA (1) | CA2085733C (enExample) |
| CZ (1) | CZ281920B6 (enExample) |
| DE (1) | DE69126980T2 (enExample) |
| FI (1) | FI925731A0 (enExample) |
| HU (1) | HUT65623A (enExample) |
| IE (1) | IE912126A1 (enExample) |
| IL (1) | IL98559A0 (enExample) |
| NO (1) | NO924940L (enExample) |
| NZ (1) | NZ238609A (enExample) |
| OA (1) | OA09723A (enExample) |
| PL (1) | PL169481B1 (enExample) |
| RU (1) | RU2080322C1 (enExample) |
| TW (1) | TW197441B (enExample) |
| WO (1) | WO1991019717A1 (enExample) |
| ZA (1) | ZA914727B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI953981A7 (fi) * | 1993-02-26 | 1995-08-24 | Schering Corp | 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi |
| US5929046A (en) * | 1994-06-08 | 1999-07-27 | Cancer Research Campaign Technology Limited | Pyrimidine and purine derivatives and their use in treating tumour cells |
| US5661153A (en) * | 1994-07-19 | 1997-08-26 | Japan Energy Corporation | 1-arylpyrimidine derivatives and pharmaceutical use thereof |
| ZA969888B (en) * | 1995-11-28 | 1997-05-26 | Schering Corp | 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones |
| US5824683A (en) * | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
| US5858694A (en) * | 1997-05-30 | 1999-01-12 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of cancerous lesions |
| CA2238283C (en) | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
| US6410584B1 (en) * | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
| US6130053A (en) * | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
| US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
| US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
| US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
| US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
| US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
| US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
| US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
| US6025394A (en) | 1999-01-29 | 2000-02-15 | Cell Pathways, Inc. | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols |
| US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
| ES2166270B1 (es) * | 1999-07-27 | 2003-04-01 | Almirall Prodesfarma Sa | Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona. |
| US6555547B1 (en) | 2000-02-28 | 2003-04-29 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative |
| US6569638B1 (en) | 2000-03-03 | 2003-05-27 | Cell Pathways, Inc | Method for screening compounds for the treatment of neoplasia |
| US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| EP1790652A1 (en) * | 2001-08-28 | 2007-05-30 | Schering Corporation | Polycyclic guanine phosphodiesterase V inhibitors |
| JP4450365B2 (ja) * | 2001-08-28 | 2010-04-14 | シェーリング コーポレイション | 多環式グアニンホスホジエステラーゼｖ阻害剤 |
| CA2459161A1 (en) | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain |
| EP1312363A1 (en) * | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Methods of treatment and kits comprising a growth hormone secretagogue |
| CN1585771A (zh) * | 2001-11-09 | 2005-02-23 | 先灵公司 | 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂 |
| US7342884B2 (en) * | 2002-03-13 | 2008-03-11 | Harmonic, Inc. | Method and apparatus for one directional communications in bidirectional communications channel |
| PT1509525E (pt) * | 2002-05-31 | 2006-12-29 | Schering Corp | Processo para preparação de xantinas inibidoras da fosfodiesterase v e de seus precursores |
| SI1509525T1 (sl) | 2002-05-31 | 2006-12-31 | Schering Corp | Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev |
| EP1648895B1 (en) * | 2003-07-31 | 2007-05-30 | Schering Corporation | Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction |
| AU2004260758B2 (en) * | 2003-08-01 | 2007-06-07 | Nippon Soda Co., Ltd. | Phenylazole compounds, production process, and antioxidants |
| TW200526664A (en) * | 2003-11-21 | 2005-08-16 | Schering Corp | Phosphodiesterase V inhibitor formulation |
| WO2006104870A2 (en) * | 2005-03-25 | 2006-10-05 | Schering Corporation | Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors |
| EP1888534B1 (en) | 2005-06-06 | 2017-07-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP1919287A4 (en) * | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| WO2007055170A1 (ja) * | 2005-11-09 | 2007-05-18 | Tosoh Corporation | パーフルオロアルキル基を有する核酸塩基類およびその製造方法 |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| WO2007143705A2 (en) * | 2006-06-06 | 2007-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2081431B1 (en) * | 2006-11-13 | 2013-01-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2089034A4 (en) * | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | NEW USES |
| JP2010530427A (ja) | 2007-06-21 | 2010-09-09 | シェーリング コーポレイション | 多環式グアニン誘導体およびその使用方法 |
| PT2240490E (pt) | 2007-12-06 | 2013-12-09 | Takeda Pharmaceutical | Compostos orgânicos |
| KR20100094551A (ko) | 2007-12-06 | 2010-08-26 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| PE20110995A1 (es) * | 2008-12-06 | 2012-02-06 | Intra Cellular Therapies Inc | DERIVADOS DE PIRROLO[3,4-e]PIRIMIDINA COMO INHIBIDORES DE PDE1 |
| EP2358723B1 (en) * | 2008-12-06 | 2015-05-13 | Intra-Cellular Therapies, Inc. | 4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors |
| SG171777A1 (en) | 2008-12-06 | 2011-07-28 | Intra Cellular Therapies Inc | Organic compounds |
| US8697710B2 (en) | 2008-12-06 | 2014-04-15 | Intra-Cellular Therapies, Inc. | Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones |
| WO2010065147A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2010065149A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US11464781B2 (en) | 2009-02-25 | 2022-10-11 | Intra-Cellular Therapies, Inc. | PDE1 inhibitors for ophthalmic disorders |
| JP5765239B2 (ja) * | 2009-03-13 | 2015-08-19 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物 |
| US9468637B2 (en) | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP6166534B2 (ja) | 2009-08-05 | 2017-07-19 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規調節タンパク質および阻害剤 |
| US20110190192A1 (en) * | 2009-12-15 | 2011-08-04 | Cebix Inc. | Methods for treating erectile dysfunction in patients with insulin-dependent diabetes |
| EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| US9371327B2 (en) | 2010-05-31 | 2016-06-21 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| EP2576551A4 (en) | 2010-05-31 | 2014-04-16 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| JP6051210B2 (ja) | 2011-06-10 | 2016-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| WO2014127331A1 (en) | 2013-02-17 | 2014-08-21 | Intra-Cellular Therapies, Inc. | Novel uses |
| ES2871327T3 (es) | 2013-03-15 | 2021-10-28 | Intra Cellular Therapies Inc | Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de enfermedades o trastornos de SNC o SNP |
| MX378194B (es) | 2013-03-15 | 2025-03-10 | Intra Cellular Therapies Inc | Compuestos organicos. |
| WO2015106032A1 (en) | 2014-01-08 | 2015-07-16 | Intra-Cellular Therapies, Inc. | Products and pharmaceutical compositions |
| ES2732442T3 (es) | 2014-06-20 | 2019-11-22 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| JP6591530B2 (ja) | 2014-08-07 | 2019-10-16 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| CN107106563B (zh) | 2014-09-17 | 2021-05-25 | 细胞内治疗公司 | 化合物和方法 |
| CN107205999B (zh) | 2014-12-06 | 2021-08-03 | 细胞内治疗公司 | 有机化合物 |
| EP3226862B1 (en) | 2014-12-06 | 2020-07-08 | Intra-Cellular Therapies, Inc. | Phosphodiesterase 2 (pde2) inhibitory compounds |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| WO2018049417A1 (en) | 2016-09-12 | 2018-03-15 | Intra-Cellular Therapies, Inc. | Novel uses |
| KR102590848B1 (ko) | 2016-12-28 | 2023-10-19 | 다트 뉴로사이언스, 엘엘씨 | Pde2 억제제로서 치환된 피라졸로피리미디논 화합물 |
| KR102794907B1 (ko) | 2017-11-27 | 2025-04-14 | 다트 뉴로사이언스, 엘엘씨 | Pde1 억제제로서의 치환된 푸라노피리미딘 화합물 |
| EP3746081A4 (en) | 2018-01-31 | 2021-10-27 | Intra-Cellular Therapies, Inc. | Novel uses |
| US12410175B2 (en) | 2019-09-03 | 2025-09-09 | Intra-Cellular Therapies, Inc. | Compounds |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE863525A (fr) * | 1977-02-14 | 1978-07-31 | Bristol Myers Co | Heterocyclopyrimidines |
| CA1095906A (en) * | 1977-02-14 | 1981-02-17 | Davis L. Temple, Jr. | Heterocyclopyrimidines, compositions and therapeutic process |
| AU623755B2 (en) * | 1989-03-29 | 1992-05-21 | Merrell Pharmaceuticals Inc. | Selective adenosine receptor compounds |
| US5064947A (en) * | 1989-03-29 | 1991-11-12 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine reseptor compounds |
| US5173492A (en) * | 1989-09-14 | 1992-12-22 | Kyowa Hakko Kogyo Co., Ltd. | s-Triazolo(3,4-I)purine derivatives |
| CA2028235C (en) * | 1989-10-20 | 1997-01-21 | Fumio Suzuki | Condensed purine derivatives |
-
1991
- 1991-06-19 IL IL98559A patent/IL98559A0/xx unknown
- 1991-06-19 NZ NZ238609A patent/NZ238609A/en unknown
- 1991-06-19 ZA ZA914727A patent/ZA914727B/xx unknown
- 1991-06-20 IE IE212691A patent/IE912126A1/en unknown
- 1991-06-20 CZ CS923749A patent/CZ281920B6/cs unknown
- 1991-06-20 AT AT91912779T patent/ATE155786T1/de not_active IP Right Cessation
- 1991-06-20 AU AU81992/91A patent/AU651607B2/en not_active Ceased
- 1991-06-20 RU RU9192016466A patent/RU2080322C1/ru active
- 1991-06-20 HU HU9204032A patent/HUT65623A/hu unknown
- 1991-06-20 PL PL91297299A patent/PL169481B1/pl unknown
- 1991-06-20 DE DE69126980T patent/DE69126980T2/de not_active Expired - Fee Related
- 1991-06-20 EP EP91912779A patent/EP0538332B1/en not_active Expired - Lifetime
- 1991-06-20 KR KR1019920703316A patent/KR960004532B1/ko not_active Expired - Fee Related
- 1991-06-20 TW TW080104761A patent/TW197441B/zh active
- 1991-06-20 JP JP3512084A patent/JPH0747589B2/ja not_active Expired - Fee Related
- 1991-06-20 US US07/949,811 patent/US5393755A/en not_active Expired - Lifetime
- 1991-06-20 WO PCT/US1991/004154 patent/WO1991019717A1/en not_active Ceased
- 1991-06-20 CA CA002085733A patent/CA2085733C/en not_active Expired - Fee Related
-
1992
- 1992-12-17 FI FI925731A patent/FI925731A0/fi not_active Application Discontinuation
- 1992-12-18 NO NO92924940A patent/NO924940L/no unknown
- 1992-12-21 OA OA60319A patent/OA09723A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO924940D0 (no) | 1992-12-18 |
| EP0538332B1 (en) | 1997-07-23 |
| JPH05508647A (ja) | 1993-12-02 |
| IL98559A0 (en) | 1992-07-15 |
| FI925731A7 (fi) | 1992-12-17 |
| AU651607B2 (en) | 1994-07-28 |
| NZ238609A (en) | 1993-12-23 |
| HUT65623A (en) | 1994-07-28 |
| AU8199291A (en) | 1992-01-07 |
| DE69126980T2 (de) | 1998-01-08 |
| CA2085733C (en) | 1996-03-05 |
| HU9204032D0 (en) | 1993-03-29 |
| ATE155786T1 (de) | 1997-08-15 |
| IE912126A1 (en) | 1992-01-01 |
| PL169481B1 (pl) | 1996-07-31 |
| TW197441B (enExample) | 1993-01-01 |
| CA2085733A1 (en) | 1991-12-22 |
| JPH0747589B2 (ja) | 1995-05-24 |
| CZ281920B6 (cs) | 1997-04-16 |
| PL297299A1 (enExample) | 1992-07-13 |
| OA09723A (en) | 1993-08-30 |
| US5393755A (en) | 1995-02-28 |
| DE69126980D1 (de) | 1997-09-04 |
| RU2080322C1 (ru) | 1997-05-27 |
| NO924940L (no) | 1992-12-18 |
| WO1991019717A1 (en) | 1991-12-26 |
| CZ374992A3 (en) | 1993-10-13 |
| KR960004532B1 (ko) | 1996-04-06 |
| EP0538332A1 (en) | 1993-04-28 |
| FI925731A0 (fi) | 1992-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW197441B (enExample) | ||
| DE69919897D1 (en) | 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel | |
| ATE155133T1 (de) | Piperazinderivate als 5-ht antagonisten | |
| DE69327913D1 (de) | 1,2,4-Oxadiazolyl-Phenoxyalkyl-isoxazole und ihre Anwendung als antivirale Mittel | |
| ES2123756T3 (es) | Derivados de piperazina. | |
| DE69431471D1 (de) | Amide derivate als 5-ht1a liganden | |
| TW281673B (enExample) | ||
| DE69104475D1 (de) | Harnstoffderivate, ihre herstellung und deren enthaltende arzneimittel. | |
| DE69416311D1 (de) | Verwendung von cephem-derivaten als antimetastatische mittel | |
| KR970706280A (ko) | 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists) | |
| ATE203533T1 (de) | INDOLDERIVATE ALS PRODRUGS VON ß5-HT1-LIKEß REZEPTOR AGONISTEN | |
| DE69403896D1 (de) | 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten | |
| TR199701289T2 (xx) | Karbapenemlerin esterleri | |
| AU4932590A (en) | Cyclic guanidines uses as calcium antagonists | |
| ATE119883T1 (de) | Thioformamidderivate. | |
| MX9704262A (es) | Piridazinonas como antagonistas del receptor endotelial. |